Authors

• Aliasger K. Salem (ORCID: https://orcid.org/0000-0002-1923-6633)
• Ryan J. Reis (ORCID: https://orcid.org/0000-0002-9831-757X)
• Jessica C. Sieren (ORCID: https://orcid.org/0000-0002-1109-7886)
• Umang Swami (ORCID: https://orcid.org/0000-0003-3518-0411)
• Sarah L. Mott (ORCID: https://orcid.org/0000-0001-9381-2080)
• K.D. Zamba (ORCID: https://orcid.org/0009-0003-0397-4804)
• Yousef Zakharia (ORCID: https://orcid.org/0000-0001-9480-2626)
• Rohan Garje (ORCID: https://orcid.org/0000-0002-7244-5602)
• Aseel O. Rataan
• Bilal Rahim
• Srija Manchkanti (ORCID: https://orcid.org/0000-0003-0244-5487)
• Matthew R. Kroll (ORCID: https://orcid.org/0009-0003-3854-0942)
• Youcef M. Rustum (ORCID: https://orcid.org/0009-0002-7831-3712)

Institutions

• University of Iowa (US)
• Roswell Park Comprehensive Cancer Center (US)
• University of Utah (US)
• Huntsman Cancer Institute (US)
• University of Iowa Hospitals and Clinics (US)
• Baptist Health South Florida (US)
• Cancer Institute of Florida (US)
• TOCA at Banner Health (US)

Publication Details

Journal

Clinical Cancer Research

Published

2025-01-29

DOI

https://doi.org/10.1158/1078-0432.ccr-24-3234

Citations

1

Primary Topic

Renal cell carcinoma treatment

Type

article

Field-Weighted Citation Impact

1.52

Funders

• Pfizer